Cue Biopharma, Inc. (CUE)
| Previous close | 1.5000 |
| Open | 1.5300 |
| Bid | 1.4100 x 200 |
| Ask | 1.4500 x 200 |
| Day's range | 1.3800 - 1.5400 |
| 52-week range | 1.3800 - 5.1200 |
| Volume | |
| Avg. volume | 257,761 |
| Market cap | 69.56M |
| Beta (5Y monthly) | 2.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.1100 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.40 |
GlobeNewswireCue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present an oral abstract and poster at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL. The presentations will highlight the Company’s Phase 1 trials of its lead interleukin 2 (IL-2)-
ZacksHere's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now
Cue Biopharma (CUE) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- Thomson Reuters StreetEvents
Q4 2023 Cue Biopharma Inc Earnings Call
Q4 2023 Cue Biopharma Inc Earnings Call
